Health
Oral GLP-1 Drug Shows Promise in New Phase 2 Trial Data
Structure Therapeutics reports encouraging Phase 2 results for its oral GLP-1 receptor agonist, advancing a pill-form alternative to injectable weight-loss and diabetes drugs.
Key Takeaways
- Structure Therapeutics reports Phase 2 data showing GSBR-1290 produces meaningful weight reduction in obesity patients
- Small-molecule design approach aims to improve oral bioavailability over peptide-based GLP-1 drugs
- GI side effects appeared at manageable rates, addressing a key tolerability challenge for the drug class
- An effective oral GLP-1 would expand access to millions who cannot or prefer not to use injectables
DE
DT Editorial AI··via endpoints.news